{"title":"Driving progress towards PrEP equity: Key changes in the 2025 BASHH/BHIVA UK PrEP guidelines","authors":"Dan Clutterbuck, Michael Brady, Alison Rodger","doi":"10.1111/hiv.70043","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Objectives</h3>\n \n <p>Success in HIV prevention interventions, including pre-exposure prophylaxis (PrEP), among gay, bisexual and other men-who-have-sex-with-men (GBMSM) has not been replicated across all communities. The 2025 BASHH/BHIVA UK PrEP Guidelines recognizes and addresses the significant barriers and constraints that existing guidance and service delivery models place on PrEP access and equity. This paper summarizes the key guideline recommendations and the rationale supporting them.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>The guidelines were developed following the methodology described in the CEG Framework for Guideline development published on the BASHH website. The writing group of clinicians, academics and community advocates incorporated input from a formal public consultation process.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>The 2025 guideline includes over 90 graded recommendations. A chapter on PrEP equity and an updated chapter on PrEP suitability and risk assessment, moving away from basing PrEP eligibility on the inclusion criteria used for clinical trials, are included. Injectable PrEP has demonstrated superiority to oral PrEP but presents challenges in delivery, so improving equity in access and uptake of existing oral PrEP options was a key priority. The guidelines simplify and clarify advice on dosing for oral PrEP and recommend new event-based dosing options for all PrEP users, including quick-start double-dose PrEP for everybody. New guidance on the use of PrEP after a potential exposure is also included.</p>\n </section>\n \n <section>\n \n <h3> Conclusions</h3>\n \n <p>The PrEP guidelines purposefully highlight equity, access and the urgent requirement to meet the needs of underserved communities as a priority. These are addressed through pragmatic and groundbreaking recommendations based on careful consideration of all available evidence.</p>\n </section>\n </div>","PeriodicalId":13176,"journal":{"name":"HIV Medicine","volume":"26 7","pages":"1125-1141"},"PeriodicalIF":2.8000,"publicationDate":"2025-06-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/hiv.70043","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"HIV Medicine","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/hiv.70043","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}
引用次数: 0
Abstract
Objectives
Success in HIV prevention interventions, including pre-exposure prophylaxis (PrEP), among gay, bisexual and other men-who-have-sex-with-men (GBMSM) has not been replicated across all communities. The 2025 BASHH/BHIVA UK PrEP Guidelines recognizes and addresses the significant barriers and constraints that existing guidance and service delivery models place on PrEP access and equity. This paper summarizes the key guideline recommendations and the rationale supporting them.
Methods
The guidelines were developed following the methodology described in the CEG Framework for Guideline development published on the BASHH website. The writing group of clinicians, academics and community advocates incorporated input from a formal public consultation process.
Results
The 2025 guideline includes over 90 graded recommendations. A chapter on PrEP equity and an updated chapter on PrEP suitability and risk assessment, moving away from basing PrEP eligibility on the inclusion criteria used for clinical trials, are included. Injectable PrEP has demonstrated superiority to oral PrEP but presents challenges in delivery, so improving equity in access and uptake of existing oral PrEP options was a key priority. The guidelines simplify and clarify advice on dosing for oral PrEP and recommend new event-based dosing options for all PrEP users, including quick-start double-dose PrEP for everybody. New guidance on the use of PrEP after a potential exposure is also included.
Conclusions
The PrEP guidelines purposefully highlight equity, access and the urgent requirement to meet the needs of underserved communities as a priority. These are addressed through pragmatic and groundbreaking recommendations based on careful consideration of all available evidence.
期刊介绍:
HIV Medicine aims to provide an alternative outlet for publication of international research papers in the field of HIV Medicine, embracing clinical, pharmocological, epidemiological, ethical, preclinical and in vitro studies. In addition, the journal will commission reviews and other feature articles. It will focus on evidence-based medicine as the mainstay of successful management of HIV and AIDS. The journal is specifically aimed at researchers and clinicians with responsibility for treating HIV seropositive patients.